Literature DB >> 2184205

Periosteal osteosarcoma of the maxilla: a case report and review of literature.

A Patterson1, R O Greer, D Howard.   

Abstract

Juxtacortical osteosarcomas, including periosteal and parosteal subtypes, are uncommon neoplasms of the jaws. In long bones, the biologic behavior of the periosteal variant is reported to be more aggressive than the parosteal tumor. Juxtacortical osteosarcoma of the jaws appears to have a slightly more favorable prognosis than in long bones, although a larger series of cases needs to be evaluated before a definitive conclusion concerning the behavior of juxtacortical osteosarcoma of the jaws can be made.

Entities:  

Mesh:

Year:  1990        PMID: 2184205     DOI: 10.1016/0278-2391(90)90246-x

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  6 in total

Review 1.  Periosteal osteosarcoma of the mandible: case report and review of the literature.

Authors:  Guo Dong Wang; Yun Fu Zhao; Yuan Liu; Lei Jiang; Xiao Zhong Jiang
Journal:  J Oral Maxillofac Surg       Date:  2011-01-26       Impact factor: 1.895

Review 2.  Periosteal osteosarcoma: a review of clinical evidence.

Authors:  Xin-Wei Liu; Ying Zi; Liang-Bi Xiang; Tian-Yu Han
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Case report 793. Periosteal osteosarcoma of the clavicle.

Authors:  Y Oda; H Hashimoto; M Tsuneyoshi; S Masuda
Journal:  Skeletal Radiol       Date:  1993       Impact factor: 2.199

4.  Case report 852. Periosteal osteosarcoma of femur.

Authors:  E R Melhem; R H Hruban; E K Fishman
Journal:  Skeletal Radiol       Date:  1994-07       Impact factor: 2.199

5.  A giant osteoma of the mandible.

Authors:  Pushkar Gawande; Vikram Deshmukh; J B Garde
Journal:  J Maxillofac Oral Surg       Date:  2011-03-25

Review 6.  The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease.

Authors:  Catarina Melim; Ivana Jarak; Francisco Veiga; Ana Figueiras
Journal:  3 Biotech       Date:  2020-03-02       Impact factor: 2.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.